Search

Your search keyword '"Caldron, Paul H."' showing total 20 results
Start Over Author "Caldron, Paul H."
20 results on '"Caldron, Paul H."'

1. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Author

Ahmed, Khalid, Alper, Jeffrey, Barkham, Nichol, Bennett, Ralph E., García, Francisco Javier Blanco, Alonso, Ricardo Blanco, Blumstein, Howard B., Brooks, Michael S., Burmester, Gerd-Rüdiger, Cagnoli, Patricia, Caldron, Paul H., Cantagrel, Alain, Chen, Der-Yuan, Churchill, Melvin A., Jr, Codding, Christine E., Combe, Benard, Deane, Peter M.G., Del Giudice, Jose, Deodhar, Atul A., Dhar, Rajat K., Dokoupilova, Eva, Egan, Rita M., Everding, Andrea, Galíndez, Eva, Genovese, Mark, Goddard, David H., Gottlieb, Alice, Goupille, Philippe, Griffin, Robert M., Gupta, Ramesh C., Hall, Stephen, Hatti, Kalpita, Howell, Mary P., Huang, Yu-Huei, Jajoo, Ramina, Janssen, Namieta M., Kiltz, Uta, Kivitz, Alan J., Klein, Steven J., Korkosz, Mariusz P., Kotha, Roshan, Kremer, Joel M., Lue, Cummins, de la Fuente, José Luis Marenco, Marzo-Ortega, Helena, Masmitja, Jordi Gratacós, Mease, Philip J., Meroni, Pier Luigi, Mueller, Eric C., Nandagudi, Anupama C., Nash, Peter, Fernández-Nebro, Antonio, Neuwelt, Clark M., Orbai, Ana Maria, Oza, Meera R., Parks, Deborah L., Pattanaik, Debendra, Rell-Bakalarska, Maria E., Rosmarin, David, Roussou, Euthalia, Rychlewska-Hanczewksa, Anna I., Sikes, David H., Stack, Michael T., Sunkureddi, Prashanth, Tahir, Hasan, Thaçi, Diamant, Tsai, Tsen-Fang, Turkiewicz, Anthony M., Unger, Leonore, Cabello, Raúl Veiga, Wagner, Ulf, Wei, Cheng-Chung, Wells, Alvin F., Youssef, Peter, Zielinska, Agnieszka, Kirkham, Bruce, Okada, Masato, Rahman, Proton, Burmester, Gerd-Ruediger, Adams, David H, Kerr, Lisa, Lee, Chin, and Shuler, Catherine L

Published
2017
Full Text
View/download PDF

6. Why do they care? Narratives of physician volunteers on motivations for participation in short-term medical missions abroad

Author

Caldron, Paul H., Impens, Ann, Pavlova, Milena, Groot, Wim, RS: CAPHRI - R2 - Creating Value-Based Health Care, Health Services Research, RS: FSE TA-TIER, Maastricht Graduate School of Governance, and TIER TA

Subjects
TRIPS, volunteering, motivation, STMM, medical mission, short-term, GLOBAL HEALTH, PROFESSIONALIZATION, OVERSEAS
Abstract

BackgroundShort-term medical missions (STMMs) refer to the provision of direct pro bono medical services in lower and middle income countries for periods ranging from days to a few weeks by physicians from rich countries. Survey data have provided limited information on demographic and professional profiles of physicians as well as monetary and manpower inputs. Understanding why physicians participate, however, remains incomplete. The study's objective was to elicit physicians' motivations directly. MethodsSemi-structured interviews of physicians identified through snowball recruiting were conducted to explore motivational themes and then analyzed using narrative software employing directed content analysis methodology. ResultsTwenty physicians from varying backgrounds and specialties were interviewed. Responses identified aspects of the decision to participate and the relative influence of economic, diplomatic, value-related, and emotive constructs. ConclusionPersonality traits may be more influential to participation than demographic, professional, or socioeconomic determinants. Word-of-mouth recruitment appears to underlie the increase in STMM activity, facilitated by information technology. Reported key motivators for physician participation in STMMs tend to parallel schools of thought regarding philanthropy and volunteering and include satisfaction from helping in challenging conditions of limited resources, learning experiences, appreciation from patients, sense of renewal, and the legacy effect of teaching.

Published
2018

9. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Author

Nash, Peter, primary, Kirkham, Bruce, additional, Okada, Masato, additional, Rahman, Proton, additional, Combe, Benard, additional, Burmester, Gerd-Ruediger, additional, Adams, David H, additional, Kerr, Lisa, additional, Lee, Chin, additional, Shuler, Catherine L, additional, Genovese, Mark, additional, Ahmed, Khalid, additional, Alper, Jeffrey, additional, Barkham, Nichol, additional, Bennett, Ralph E., additional, García, Francisco Javier Blanco, additional, Alonso, Ricardo Blanco, additional, Blumstein, Howard B., additional, Brooks, Michael S., additional, Burmester, Gerd-Rüdiger, additional, Cagnoli, Patricia, additional, Caldron, Paul H., additional, Cantagrel, Alain, additional, Chen, Der-Yuan, additional, Churchill, Melvin A., additional, Codding, Christine E., additional, Deane, Peter M.G., additional, Del Giudice, Jose, additional, Deodhar, Atul A., additional, Dhar, Rajat K., additional, Dokoupilova, Eva, additional, Egan, Rita M., additional, Everding, Andrea, additional, Galíndez, Eva, additional, Goddard, David H., additional, Gottlieb, Alice, additional, Goupille, Philippe, additional, Griffin, Robert M., additional, Gupta, Ramesh C., additional, Hall, Stephen, additional, Hatti, Kalpita, additional, Howell, Mary P., additional, Huang, Yu-Huei, additional, Jajoo, Ramina, additional, Janssen, Namieta M., additional, Kiltz, Uta, additional, Kivitz, Alan J., additional, Klein, Steven J., additional, Korkosz, Mariusz P., additional, Kotha, Roshan, additional, Kremer, Joel M., additional, Lue, Cummins, additional, de la Fuente, José Luis Marenco, additional, Marzo-Ortega, Helena, additional, Masmitja, Jordi Gratacós, additional, Mease, Philip J., additional, Meroni, Pier Luigi, additional, Mueller, Eric C., additional, Nandagudi, Anupama C., additional, Nash, Peter, additional, Fernández-Nebro, Antonio, additional, Neuwelt, Clark M., additional, Orbai, Ana Maria, additional, Oza, Meera R., additional, Parks, Deborah L., additional, Pattanaik, Debendra, additional, Rell-Bakalarska, Maria E., additional, Rosmarin, David, additional, Roussou, Euthalia, additional, Rychlewska-Hanczewksa, Anna I., additional, Sikes, David H., additional, Stack, Michael T., additional, Sunkureddi, Prashanth, additional, Tahir, Hasan, additional, Thaçi, Diamant, additional, Tsai, Tsen-Fang, additional, Turkiewicz, Anthony M., additional, Unger, Leonore, additional, Cabello, Raúl Veiga, additional, Wagner, Ulf, additional, Wei, Cheng-Chung, additional, Wells, Alvin F., additional, Youssef, Peter, additional, and Zielinska, Agnieszka, additional

Published
2017
Full Text
View/download PDF

17. Why (not) go east? Comparison of findings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe, and other parts of the world

Author

Caldron,Paul H, Gavrilova,Svetlana I, Kropf,Siegfried, Caldron,Paul H, Gavrilova,Svetlana I, and Kropf,Siegfried

Abstract

Paul H Caldron1, Svetlana I Gavrilova2, Siegfried Kropf31Midwestern University, Arizona College of Osteopathic Medicine, Glendale, AZ, USA; 2Mental Health Research Center of the Russian Academy of Medical Sciences, Moscow, Russian Federation; 3Institute for Biometrics und Medical Informatics, Otto von Guericke University of Magdeburg, Magdeburg, GermanyAbstract: Since the mid-1990s, investigational sites in the countries of Central and Eastern Europe (CEE) have been increasingly utilized by pharmaceutical companies because of their high productivity in terms of patient enrolment into clinical trials. Based on the FDA's publicly accessible Clinical Investigator Inspection List, we present an analysis of findings and outcome classifications from FDA inspections during Investigational New Drug (IND) studies and compare the results for the CEE region to those from Western European countries and the USA. Data from all 5531 FDA clinical trials inspections that occurred between 1994 (when the FDA first performed inspections in CEE) and the end of 2010 were entered into the database for comparative analysis. Of these, 4865 routine data audit (DA) inspections were analyzed: 401 from clinical trials performed in Western Europe, 230 in CEE, 3858 in the USA, and 376 in other countries. The average number of deficiencies per inspection ranged between 0.99 for CEE and 1.97 in Western Europe. No deficiencies were noted during 16.6%, 39.0%, and 21.5% of the inspections in Western Europe, CEE and USA, respectively. The percentages of inspections after which no follow-up action was indicated were 36.9% for Western Europe, 55.7% for CEE, and 44.3% for US sites. CEE was also the region with the lowest percentage of inspections that required official or voluntary action. On the basis of FDA inspection data, the high productivity of CEE sites appears to be accompanied by regulatory compliance as well as by data quality standards that are not inferior to those in Western regions.K

Published
2012

20. Why do they care? Narratives of physician volunteers on motivations for participation in short-term medical missions abroad.

Author

Caldron PH, Impens A, Pavlova M, and Groot W

Subjects
Adult, Aged, Female, Humans, Interviews as Topic, Male, Middle Aged, Narration, Personality, Socioeconomic Factors, Medical Missions, Motivation, Physicians psychology, Volunteers psychology
Abstract

Background: Short-term medical missions (STMMs) refer to the provision of direct pro bono medical services in lower and middle income countries for periods ranging from days to a few weeks by physicians from rich countries. Survey data have provided limited information on demographic and professional profiles of physicians as well as monetary and manpower inputs. Understanding why physicians participate, however, remains incomplete. The study's objective was to elicit physicians' motivations directly., Methods: Semi-structured interviews of physicians identified through snowball recruiting were conducted to explore motivational themes and then analyzed using narrative software employing directed content analysis methodology., Results: Twenty physicians from varying backgrounds and specialties were interviewed. Responses identified aspects of the decision to participate and the relative influence of economic, diplomatic, value-related, and emotive constructs., Conclusion: Personality traits may be more influential to participation than demographic, professional, or socioeconomic determinants. Word-of-mouth recruitment appears to underlie the increase in STMM activity, facilitated by information technology. Reported key motivators for physician participation in STMMs tend to parallel schools of thought regarding philanthropy and volunteering and include satisfaction from helping in challenging conditions of limited resources, learning experiences, appreciation from patients, sense of renewal, and the legacy effect of teaching., (Copyright © 2017 John Wiley & Sons, Ltd.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results